Position Statement: BOPA supports the withdrawal of histamine 2 (H2) antagonists from paclitaxel pre-medication regimens following publication of research which demonstrates their lack of effect. January 2023
BOPA is pleased to announce publication of a position statement confirming our support for removal of H2 antagonists from paclitaxel pre-medication regimens. This position statement follows on from the excellent work of the BOPA community supporting a national, multi-centre project and subsequent publication of the results by the research team of BOPA members. The executive committee would like to thank the BOPA membership for their support in this project and hope that this position statement supports a wider change in practice across the UK.
